Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

Jerry S. Wolinsky, Ponnada A. Narayana, Flavia Nelson, Sushmita Datta, Paul O'Connor, Christian Confavreux, Giancarlo Comi, Ludwig Kappos, Tomas P. Olsson, Philippe Truffinet, Lin Wang, Aaron Miller, Mark S. Freedman

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

Objective: The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance imaging (MRI). Methods: Patients (n=1088) with relapsing MS were randomized to once-daily teriflunomide 7 mg or 14 mg, or placebo, for 108 weeks. MRI was recorded at baseline, 24, 48, 72 and 108 weeks. Annualized relapse rate and confirmed progression of disability (sustained ≤12 weeks) were the primary and key secondary outcomes. The principal MRI outcome was change in total lesion volume. Results: After 108 weeks, increase in total lesion volume was 67.4% (p=0.0003) and 39.4% (p=0.0317) lower in the 14 and 7 mg dose groups versus placebo. Other measures favoring teriflunomide were accumulated enhanced lesions, combined unique activity, T2-hyperintense and T1-hypointense component lesion volumes, white matter volume, and a composite MRI score; all were significant for teriflunomide 14 mg and most significant for 7 mg versus placebo. Conclusions: Teriflunomide provided benefits on brain MRI activity across multiple measures, with a dose effect evident on several markers. These effects were also consistent across selected subgroups of the study population. These findings complement clinical data showing significant teriflunomide- related reductions in relapse rate and disease progression, and demonstrate containment of MRI-defined disease progression.

Original languageEnglish (US)
Pages (from-to)1310-1319
Number of pages10
JournalMultiple Sclerosis Journal
Volume19
Issue number10
DOIs
StatePublished - Sep 2013

Keywords

  • Teriflunomide
  • clinical trial
  • disease-modifying therapy
  • magnetic resonance imaging
  • multiple sclerosis
  • phase III

Fingerprint

Dive into the research topics of 'Magnetic resonance imaging outcomes from a phase III trial of teriflunomide'. Together they form a unique fingerprint.

Cite this